Federal jury asks Gilead to pay Merck $2.54 billion in royalties in patent infringement case - Technical.ly Delaware


Dec. 20, 2016 12:25 pm

Federal jury asks Gilead to pay Merck $2.54 billion in royalties in patent infringement case

Bloomberg called it the biggest patent infringement decision in the history of the U.S.


(Photo by Flickr user samantha celera, used under a Creative Commons license)

Last week, pharma company Merck & Co. received $2.54 billion in royalties from competitor Gilead Sciences in a patent infringement case, Bloomberg reported. This took place in the U.S. District Court in Wilmington.

“The jury in Wilmington, Delaware, deliberated for less than two hours and rejected Gilead’s arguments that Merck’s patent is invalid,” according to Bloomberg. “The judge in the case had already decided that Merck’s patent was infringed by Gilead’s Sovaldi and Harvoni, which account for more than half the drugmaker’s revenue.”

It was described as the biggest patent infringement in the history of the United States by Bloomberg. Per the story:

“The infringement also was found to be willful, meaning the judge could increase the damage award by as much as three times the amount set by the jury. The jury said on Thursday that Gilead owed 10 percent royalties on $25.4 billion in total sales for the two drugs.”

Now let’s rewind for a minute and look at some history. The biggest beneficiary of this lawsuit was Merck’s subsidary, Idenix. Merck bought Idenix for $3.85 billion a couple of years ago, which was three times its value in 2014. As a result of the purchase, Merck’s Hepatitis C drug portfolio got a boost, a market that Gilead was leading prior to Merck purchasing Idenix. It’s been a space race between both companies in the Hep C market ever since.

Merck donated lab equipment to the new Pennovation Center in University City in Philadelphia a couple of months ago. The company also has a workspace at Drexel’s new incubator, space @3401. Over the summer, Merck met with DreamIt’s spring 2016 cohort.


Companies: Merck
Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action


Is government-moderated social media near?

This podcast wants to ease the stress of Delaware’s lawyers

The Delaware Chancery Court case that was like ‘TMZ on steroids’



Verizon is looking for the brightest ideas on how to use its 5G technology

Philadelphia, PA - Center City


Business Architect

Apply Now


Philadelphia Home

Social Media Catalyst

Apply Now

Baltimore, Brooklyn, D.C., Delaware, Philadelphia

Vistar Media

Software Engineer

Apply Now

Learn the basics of protecting your intellectual property

Biotech faces setbacks after Incyte’s experimental cancer drug fails testing

Tech2gether 2017 is seeking speakers in fintech and legaltech



Escape the August heat with cool AI tech

Malvern, PA


Senior Front End Engineer – CX Journey Lab

Apply Now


Marlette Funding

Production Support Analyst

Apply Now



Associate Marketing Specialist

Apply Now

Sign-up for daily news updates from Technical.ly Delaware

Do NOT follow this link or you will be banned from the site!